

Quercis is a Late Clinical Stage Biotech Startup that plans to disrupt the **US\$ 50bn** cancer immunotherapy **PD-1/PD-L1, VEGF** and **US\$ 30bn** thrombosis prevention markets

The Lead Asset is an **Isoquercetin based drug code-named Kinisoquin™** and in combination with **Zafirlukast**, a repurposed Leucotriene Inhibitor, will be a potentially Best-in-Class Oral Therapeutic overcoming the main unmet medical needs in the PD-1/PDL1 and VEGF market:

- **Potential efficacy advantages:** Better response in solid tumors (higher penetration into tumor tissue and higher target engagement).
- **Potential safety advantages:** Better management of immune-related side effects (shorter half-life allows faster washout); potential for reduced clinic-based infection; **strong inhibition of PDI leakage and Tissue Factor Reduction activity reduces risk of thrombosis**
- **Potential for increased penetration** as an oral asset reduces burden to patients and to the healthcare system

Kinisoquin™ is a **multi-dimensional therapeutic asset** (MDTA) targeting **PD-L1 * PDI * VEGF * TF *** as well as inflammasome triggering through **TMEM176** allowing for development in multiple indications. The Combo improves outcomes significantly as it is synergistic with Kinisoquin™. Both Kinisoquin™ and the Combo significantly improve the effects of Keytruda® and improve further a combination of Cisplatin™ and Gemcitabine® while reducing the risk of Cancer Associated Thrombosis. **TMEM176b and PDI inhibition** are being used to develop next-generation *anti-thrombotics* that turn off blood clotting mechanisms inside the vascular system unlike anticoagulants which thin the blood and have significant adverse effects such as bruising and bleeding.

Kinisoquin™ is a **Phase 3 Clinical Asset** “*The Effect of Isoquercetin on Thromboembolic Events in Patients with Metastatic Pancreatic Cancer*” under FDA SPA <https://clinicaltrials.gov/study/NCT06861088?term=NCT06861088&rank=1>. Two additional Phase 3 clinical trials are currently being initiated (a) lowering D-Dimer and prevention of **VTE in Ovarian Cancer** together with NIH and MSKCC and reduction of whole blood coagulation and crises in **Sickle Cell Disease (SCD)** respectively.

Good POC in Neurology (ALS) with the Combo ready to start Phase 2/3 adaptive Clinical Trial. Thrombo-R™ is a diagnostic test in development that could allow early warning of imminent thrombotic events. The company has a robust phase 2 pipeline.

Robust Patent Portfolio extending to 2045 includes synergy of two of our investigational drugs in re-sensitization of off-patent drugs with fresh patents providing 20 years of protection in each case. A Zafirlukast Analogue has been synthesized and is >10X more effective than Zafirlukast with less than 25% of the toxicity of the original drug

Scientific Advisory Board consists of Global A-Team in Thrombosis, Oncology and Neurology

Competitors include LMWH, DOAC's (Rivaroxaban or Xarelto and Apixaban or Eliquis) and future Factor 11a inhibitors including Bayer's Asundexian (failed) and BMS' Milvexian (in Phase 3) and AbelaCimab (in Phase 3) an injectable long-acting Factor 11a anticoagulant acquired by Novartis in its Anthos buyout in 2/25, representing a US\$ > 30bn market. **All** these competitive assets are anticoagulants which thin the blood and have significant adverse effects such as bruising and bleeding. Kinisoquin™ and the Combo can be used with almost any existing Chemotherapy or Immune Therapy.

Recent M&A transactions around competitive products include Novartis' purchase of Anthos (2/2025) for consideration including milestones of USD 3.1Bn and Merck's in-licensing of an investigational PD-1 / VEGF bispecific antibody recruiting in Phase 1 from LaNova Medicines for consideration including milestones of USD 3.3Bn addressing a fast-growing US\$ >50Bn immune oncology market. Pfizer and 3SBio deal for \$1.25 billion upfront and \$4.8 billion in development, regulatory and commercial milestones plus potentially tiered double-digit royalties on sales of SSGJ-707 if it reaches the market. **Quercis' differentiator is that our PD-L1 / VEGF drug combo is oral (capsules) and also inhibits Tissue Factor Expression while all existing PD-L1 and VEGF drugs increase Tissue Factor expression which adds significantly to the risk of Cancer Associated Thrombosis.**

*Management believes **Quercis' investigational drugs and drug combinations are better positioned to target PD-L1 and VEGF in cancer while simultaneously reducing the added thrombosis risk posed by VEGF inhibitors.** Should our Phase 2 results in prevention of VTE in cancer <https://doi.org/10.1172/jci.insight.125851> be confirmed in our ongoing Phase 3 study, our assets will potentially become **Best-in-Class assets** in both the **immune oncology and anti-thrombotic markets**, treating the cancers themselves as well as preventing Cancer Associated Thrombosis a major adverse event in cancer therapies. The fact that our drugs can be taken orally avoids costly hospital visits and reduces infection related to infusions and catheter-associated complications.*